Population impact of risk-based lung cancer screening on late-stage incidence in Greater Manchester.

Summary

Using a population-level difference-in-differences analysis, community-based, risk-targeted LDCT screening in a highly deprived region was associated with a 22% reduction in late-stage lung cancer incidence among invited adults aged 55–80. This real-world evidence supports screening effectiveness beyond trials.

Key Findings

• Community LDCT screening was associated with a 22% reduction in late-stage lung cancer incidence among adults aged 55–80.
• Difference-in-differences modeling contrasted the screening region with four neighboring regions without screening.
• Effect observed in a socioeconomically deprived population, highlighting equity gains with targeted implementation.

Clinical Implications

Supports implementing and sustaining community-based risk-targeted LDCT screening in deprived areas, with attention to outreach, adherence, and diagnostic follow-up to maximize stage shift.

Limitations

• Abstract lacks exact IRR value; potential residual confounding and generalizability beyond the region.
• Outcome is late-stage incidence (surrogate for mortality) rather than mortality itself.

Future Directions

Evaluate mortality, cost-effectiveness, and program fidelity across diverse regions; optimize risk models, adherence strategies, and diagnostic pathways to sustain stage shift.